Published: 30 January 2023
Author(s): R. Del Pozo, I. Blanco, M. López-Meseguer, P. Escribano-Subías, A. Cruz Utrilla
Issue: May 2023
Section: Letter to the Editor

The prostanoid analog epoprostenol, the first approved targeted therapy for pulmonary arterial hypertension (PAH), is also the only one that has shown any benefit for survival vs. placebo in PAH patients [1]. However, its complex route of administration (continuous intravenous infusion) and potentially serious administration-related side effects have limited its use in clinical practice [1,2]. Subsequent prostanoid analogs have had a limited use due to the pain associated with infusion (treprostinil, subcutaneous), frequent dosing (iloprost, inhaled), and prostanoid-associated side effects [2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.